Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

PEGPH20 Misses OS Endpoint in Metastatic Pancreatic Cancer

November 4th 2019

The investigational agent pegvorhyaluronidase alfa in combination with gemcitabine and nab-paclitaxel did not show an improvement in overall survival compared with gemcitabine and nab-paclitaxel alone in patients with metastatic pancreatic cancer, missing the primary endpoint of the phase III HALO-109-301 trial.

Wnt Pathway Emerges as Attractive Target in CRC

November 4th 2019

Lukas E. Dow, PhD, discusses ongoing research evaluating Wnt as a potential target in colorectal cancer.

Genetic Testing Guides mCRC Treatment

November 4th 2019

Al B. Benson, MD, discusses personalized treatment strategies for patients with metastatic colorectal cancer.

NGS Is Critical Component in Guiding Advanced Gastric/GEJ Cancer Treatment

November 2nd 2019

Manish A. Shah, MD, discusses ongoing research evaluating immunotherapy and other novel treatments in advanced gastric and gastroesophageal junction cancer.

Dr. Kaubisch on Treatment Options for HCC

November 2nd 2019

Andreas Kaubisch, MD, discusses available treatment options for hepatocellular carcinoma.

Dr. Benson on Frontline Treatment Considerations in mCRC

November 1st 2019

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Hepatic Infusion Can Convert CRC Liver Metastases to Operable State

November 1st 2019

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

Dr. Abou-Alfa on the Results of the ClarIDHy Trial in Advanced Cholangiocarcinoma

November 1st 2019

Ghassan K. Abou-Alfa, MD, discusses the results of the phase III ClarIDHy trial in advanced cholangiocarcinoma.

Deeper Understanding of NETs Biology May Hold Key to Therapeutic Advances

October 31st 2019

Lakshmi N. Rajdev, MD, discusses classifying and grading neuroendocrine tumors (NETs), treating patients with NETs, and novel therapeutic strategies in the pipeline.

MRTX849 Active in KRAS G12C+ NSCLC and CRC

October 29th 2019

The investigational KRAS G12C inhibitor MRTX849 demonstrated clinical activity in patients with non–small cell lung cancer and colorectal cancer.

Targeting Wnt in BRAF-Mutant Colorectal Cancer

October 28th 2019

Luke Dow, PhD, discusses phase I trials targeting the Wnt signaling pathway in colorectal cancer.

FDA Will Split Avapritinib GIST NDA Into Separate Submissions

October 28th 2019

The FDA has informed Blueprint Medicines that it intends to split the proposed indications for its agent avapritinib into two separate new drug applications for patients with gastrointestinal stromal tumor (GIST): one for patients with PDGFRA exon 18–mutant disease regardless of prior therapy, and one for fourth-line GIST.

MCLA-128 Shows Clinical Activity in NRG1+ Solid Tumors

October 28th 2019

MCLA-128, an investigational bispecific HER2/HER3 antibody, demonstrated radiological and clinical responses in patients with metastatic pancreatic ductal adenocarcinoma and metastatic non–small cell lung cancer who have NRG1 fusions.

Addressing the Needs of Molecular Subgroups in CRC

October 28th 2019

Benjamin Weinberg, MD, discusses the treatment options available for the various subpopulations in metastatic colorectal cancer.

Dr. Corcoran on Immunotherapy for Microsatellite Stable/Instable CRC

October 26th 2019

Ryan B. Corcoran, MD, PhD, discusses immunotherapy options for patients with microsatellite stable versus microsatellite instability–high colorectal cancer.

Ongoing Research in Pancreatic Cancer Focusing on Molecular Targets

October 25th 2019

Eileen M. O’Reilly, MD, discusses emerging strategies in pancreatic cancer.

Dr. Benson on Sequencing Strategies with Cetuximab in CRC

October 25th 2019

Al B. Benson, MD, discusses the optimal sequencing of the EGFR inhibitor cetuximab for patients with RAS wild-type colorectal cancer.

Early Findings Support Novel Regimen for Unresectable HCC

October 24th 2019

Atezolizumab (Tecentriq) plus bevacizumab (Avastin) resulted in clinically meaningful and durable objective responses as first-line therapy for patients with previously untreated, unresectable disease.

Pivotal Study Examines Blood Test as CRC Screening Method

October 24th 2019

In an effort to improve colorectal cancer screening rates via a less invasive method, the registrational ECLIPSE is evaluating the performance of the LUNAR-2 blood test in detecting colorectal cancer in average-risk adults.